# Aurantiamide acetate

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/aurantiamide-acetate
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-29
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Aurantiamide acetate salt, N-acetyl aurantiamide, Dipeptide C27H28N2O4, Aurantiamide acetic acid derivative

## Overview

Aurantiamide acetate is a synthetic dipeptide derivative composed of a phenylalanine-benzylamine scaffold with an acetate moiety, studied primarily for its [anti-inflammatory](/ingredients/condition/inflammation) and potential [neuroprotective](/ingredients/condition/cognitive) properties. Its proposed mechanisms involve modulation of inflammatory signaling pathways and inhibition of P-glycoprotein, a membrane efflux transporter that governs drug bioavailability.

## Health Benefits

• Potential [anti-inflammatory](/ingredients/condition/inflammation) properties as suggested by product literature, though specific targets are not detailed. • Predicted to inhibit P-glycoprotein modestly, which may influence drug absorption and distribution. • Computational predictions suggest CYP enzyme inhibition, indicating possible effects on drug [metabolism](/ingredients/condition/weight-management). • High predicted plasma protein binding could affect drug efficacy and distribution. • Predicted moderate intestinal absorption suggests potential for oral bioavailability.

## Mechanism of Action

Aurantiamide acetate is predicted to inhibit P-glycoprotein (ABCB1), an ATP-dependent efflux pump on intestinal and blood-brain barrier membranes, potentially increasing intracellular concentrations of co-administered substrates. Computational docking models also suggest inhibitory interactions with CYP3A4 and CYP2C9 enzymes in the hepatic cytochrome P450 system, which could alter the metabolic clearance of numerous drugs. Additionally, proposed anti-inflammatory activity may involve downregulation of NF-κB-mediated [pro-inflammatory cytokine](/ingredients/condition/inflammation) expression, though specific receptor binding data remain unpublished.

## Clinical Summary

To date, no published randomized controlled trials or peer-reviewed human clinical studies specifically investigate aurantiamide acetate as an isolated supplement ingredient. Available evidence is largely derived from in silico computational predictions, in vitro cell-line assays, and product marketing literature, none of which establish efficacy in human populations. Some preclinical data from related dipeptide analogs suggest modest [anti-inflammatory](/ingredients/condition/inflammation) effects at micromolar concentrations in cell culture models, but dose-response relationships in vivo have not been established. The overall evidence base is preliminary, and claims of clinical benefit should be interpreted with significant caution until controlled human trials are conducted.

## Nutritional Profile

Aurantiamide acetate is a dipeptide derivative (N-benzoyl-L-phenylalanyl-L-phenylalanine acetate ester) and is not a conventional nutritional ingredient; it does not contribute meaningful macronutrients, micronutrients, vitamins, minerals, or dietary fiber. As a bioactive small molecule (molecular weight ~446.5 g/mol), it is classified under specialized phytochemical/pharmaceutical compounds rather than nutritional categories. It is naturally occurring in plants such as Aegle marmelos and certain Zanthoxylum species, typically present in trace concentrations (microgram-to-milligram range per gram of plant extract). Its primary relevance is pharmacological rather than nutritional: it contains two phenylalanine residues linked by a benzoyl group with an acetate moiety, contributing negligible caloric value at bioactive doses. Bioavailability is predicted to be influenced by high plasma protein binding (estimated >90% based on computational models) and modest P-glycoprotein inhibition, suggesting variable absorption dependent on gut transporter activity. No established Dietary Reference Intake (DRI) or Recommended Daily Allowance (RDA) exists. Protein/amino acid contribution is structurally present (two phenylalanine units) but nutritionally insignificant at typical exposure levels. Fat and carbohydrate content: none intrinsic to the molecule itself.

## Dosage & Preparation

No clinically studied dosage ranges or forms are reported, as no human clinical studies have been conducted. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

No formal human safety trials have been conducted for aurantiamide acetate, making its adverse effect profile largely unknown and its use speculative from a clinical standpoint. Its predicted inhibition of P-glycoprotein raises concern for interactions with drugs such as digoxin, cyclosporine, and certain chemotherapy agents whose bioavailability is regulated by ABCB1 efflux. Predicted CYP3A4 and CYP2C9 inhibition suggests potential interactions with warfarin, statins, benzodiazepines, and other hepatically metabolized medications, which could increase plasma levels and toxicity risk. Pregnant and breastfeeding individuals, as well as those on polypharmacy regimens, should avoid this compound entirely until safety data are available.

## Scientific Research

There are no human clinical trials or meta-analyses found for aurantiamide acetate. The compound is classified as preclinical in ChEMBL, with no PubMed PMIDs available for human studies.

## Historical & Cultural Context

No traditional or historical medicinal uses for aurantiamide acetate are documented in the research. It does not appear in any specific cultural or historical medicinal systems.

## Synergistic Combinations

Curcumin, Omega-3 fatty acids, Resveratrol, Green tea extract, Quercetin

## Frequently Asked Questions

### What is aurantiamide acetate used for?

Aurantiamide acetate is primarily referenced in supplement contexts for its potential anti-inflammatory properties and its predicted ability to inhibit P-glycoprotein, an efflux transporter that affects drug and nutrient absorption. However, no human clinical trials support specific therapeutic uses, and its application remains experimental based on computational and in vitro data only.

### Does aurantiamide acetate inhibit P-glycoprotein?

Computational models predict that aurantiamide acetate modestly inhibits P-glycoprotein (ABCB1), a membrane-bound efflux pump critical for limiting intestinal absorption and brain penetration of many compounds. This inhibition, if confirmed in vivo, could theoretically increase bioavailability of co-administered P-gp substrate drugs like digoxin or loperamide, raising the risk of unintended drug accumulation.

### Can aurantiamide acetate interact with medications?

Yes, aurantiamide acetate carries a meaningful theoretical drug interaction risk based on its predicted inhibition of CYP3A4, CYP2C9, and P-glycoprotein. Drugs metabolized by these pathways — including warfarin, cyclosporine, certain statins, and antiepileptics — could accumulate to higher plasma concentrations, increasing the risk of toxicity. Anyone on prescription medications should consult a healthcare provider before considering this supplement.

### Is aurantiamide acetate a natural compound?

Aurantiamide acetate is a synthetic dipeptide derivative, not typically found in significant quantities in whole foods, though structurally related dipeptides occur naturally in some plant and fungal sources. It consists of a phenylalanine-derived backbone coupled to a benzylamine group with an acetate salt form, a structure that is generally produced through chemical synthesis for research or supplement manufacturing purposes.

### What is the recommended dosage of aurantiamide acetate?

No evidence-based recommended dosage for aurantiamide acetate has been established in humans, as no clinical pharmacokinetic or dose-finding studies have been published to date. Doses appearing in commercial supplement formulations are not standardized and lack safety validation. Without established pharmacokinetic data on absorption, half-life, or therapeutic window, any dosage in current products is speculative.

### How does aurantiamide acetate affect drug bioavailability?

Aurantiamide acetate's predicted P-glycoprotein inhibition and high plasma protein binding may alter the absorption and distribution of certain medications, potentially increasing or decreasing their bioavailability. This means drugs transported by P-glycoprotein or highly protein-bound medications could have altered blood levels when taken concurrently with aurantiamide acetate. The clinical significance of these effects depends on the specific drug, dose, and individual factors. Consultation with a healthcare provider is recommended before combining aurantiamide acetate with medications that have narrow therapeutic windows.

### What does current research reveal about aurantiamide acetate's anti-inflammatory mechanisms?

While product literature suggests anti-inflammatory potential, the specific molecular targets and pathways through which aurantiamide acetate exerts these effects have not been clearly detailed in available scientific literature. Most evidence supporting its anti-inflammatory properties comes from computational predictions and in vitro studies rather than robust clinical trials. Limited human research means the efficacy and potency of aurantiamide acetate as an anti-inflammatory agent remain largely unconfirmed. Further clinical investigation is needed to establish its role in inflammatory conditions.

### Could aurantiamide acetate affect the metabolism of multiple drug classes through CYP enzyme inhibition?

Computational predictions suggest aurantiamide acetate may inhibit cytochrome P450 enzymes, which are responsible for metabolizing a wide range of medications including statins, anticoagulants, and antihistamines. This predicted CYP inhibition could potentially slow drug metabolism and increase drug concentrations in the body, elevating the risk of adverse effects. However, these effects are currently based on computational modeling rather than confirmed human studies. Anyone taking medications metabolized by CYP enzymes should consult their healthcare provider before using aurantiamide acetate.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*